Response to brigatinib targeted therapy in non-small cell lung cancer harboring epidermal growth factor receptor exon 19 deletion, t790m, and cis-c797s triple mutations: a case report

HIGHLIGHTS

• who: Zi-Wei Chen and colleagues from the Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan have published the paper: Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report, in the Journal: (JOURNAL) of 22/Nov/2022
• what: The authors report a successful case of using brigatinib alone to overcome del19/T790M/cis-C797 mutations after progression with afatinib and osimertinib therapy.

SUMMARY

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.